Alpha-Gal Syndrome Managed With Omalizumab for Perioperative Optimization of Total Hip Arthroplasty
JBJS Case Connector · 2026
DOI: 10.2106/jbjs.cc.25.00691 ↗Kurz gefasst
Fallbericht in der Zeitschrift JBJS Case Connector, 2026. Verfasst von Anita Kohli-Pamnani und 5 weiteren Autor:innen. Beteiligte Einrichtung: Section of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut. Hauptthemen laut MEDLINE: Omalizumab, Anti-Allergic Agents, Arthroplasty, Replacement, Hip, Food Hypersensitivity. Die Arbeit nennt 22 Literaturangaben.
Abstract (Originalsprache)
Case: A 65-year-old woman with alpha-gal syndrome (AGS) required total hip arthroplasty. Laboratories revealed galactose-alpha-1,3-galactose immunoglobulin E 0.4 kU/L (abnormal ≥ 0.1 kU/L). In the absence of published guidelines for perioperative management of AGS, we used a pragmatic approach incorporating omalizumab. Conclusion: Perioperative management of AGS incorporated omalizumab injections, avoidance of high-risk medications and surgical materials containing mammalian derivatives, and pretreatment (corticosteroids, H1 and H2 antihistamines, montelukast). She tolerated hip arthroplasty without perioperative anaphylaxis or AGS symptoms by 4 months of follow-up. High-risk medications include propofol (may contain glycerol), analgesics (gelatin, magnesium stearate, lactose), and heparin (porcine, bovine).
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Section of Rheumatology, Allergy and Immunology, Department of Internal Medicine, Yale University School of Medicine, New Haven, Connecticut.
- Department of Orthopedics and Rehabilitation, Yale-New Haven Hospital, New Haven, Connecticut.
- Department of Anesthesiology, Yale University School of Medicine, New Haven, Connecticut.
- Hip and Knee Joint Reconstruction Division, Department of Orthopedics and Rehabilitation, Yale University School of Medicine, New Haven, Connecticut.
ORCID-Profile: Anita Kohli-Pamnani, Mario Rodenas, Bianca Audrey Duah, Jeremy Ansah-Twum, Marcelle Blessing, Elie Mansour
Zitieren
APA
Kohli-Pamnani, A., Rodenas, M., Duah, B. A., Ansah-Twum, J., Blessing, M., & Mansour, E. (2026). Alpha-Gal Syndrome Managed With Omalizumab for Perioperative Optimization of Total Hip Arthroplasty. JBJS Case Connector. https://doi.org/10.2106/jbjs.cc.25.00691
Vancouver
Kohli-Pamnani A, Rodenas M, Duah BA, Ansah-Twum J, Blessing M, Mansour E. Alpha-Gal Syndrome Managed With Omalizumab for Perioperative Optimization of Total Hip Arthroplasty. JBJS Case Connector. 2026. doi:10.2106/jbjs.cc.25.00691
BibTeX
@article{KohliPamnani2026,
author = {Kohli-Pamnani, Anita and Rodenas, Mario and Duah, Bianca Audrey and Ansah-Twum, Jeremy and Blessing, Marcelle and Mansour, Elie},
title = {Alpha-Gal Syndrome Managed With Omalizumab for Perioperative Optimization of Total Hip Arthroplasty},
journal = {JBJS Case Connector},
year = {2026},
doi = {10.2106/jbjs.cc.25.00691}
}
EUVIMED